{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:47:47Z","timestamp":1790750867969,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the risk for new vertebral, nonvertebral, and hip fractures over 36 months in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. Whereas discontinuation of denosumab has been associated with transient increases in bone remodeling and declines in bone mineral density (BMD), the effect on fracture risk during treatment cessation is not as well characterized. To understand the fracture incidence between treatment groups after cessation of investigational product, we evaluated subjects in FREEDOM who discontinued treatment after receiving two to five doses of denosumab or placebo, and continued study participation for \u22657 months. The off-treatment observation period for each individual subject began 7 months after the last dose and lasted until the end of the study. This subgroup of 797 subjects (470 placebo, 327 denosumab), who were evaluable during the off-treatment period, showed similar baseline characteristics for age, prevalent fracture, and lumbar spine and total hip BMD T-scores. During treatment, more placebo-treated subjects as compared with denosumab-treated subjects sustained a fracture and had significant decreases in BMD. During the off-treatment period (median 0.8 years per subject), 42% versus 28% of placebo- and denosumab-treated subjects, respectively, initiated other therapy. Following discontinuation, similar percentages of subjects in both groups sustained a new fracture (9% placebo, 7% denosumab), resulting in a fracture rate per 100 subject-years of 13.5 for placebo and 9.7 for denosumab (hazard ratio [HR] 0.82; 95% confidence interval [CI], 0.49\u20131.38), adjusted for age and total hip BMD T-score at baseline. There was no apparent difference in fracture occurrence pattern between the groups during the off-treatment period. In summary, there does not appear to be an excess in fracture risk after treatment cessation with denosumab compared with placebo during the off-treatment period for up to 24 months. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1808","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T17:39:07Z","timestamp":1351532347000},"page":"746-752","source":"Crossref","is-referenced-by-count":133,"title":["Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial"],"prefix":"10.1093","volume":"28","author":[{"given":"Jacques P","family":"Brown","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec\u2013Centre Hospitalier de l'Universit\u00e9 Laval (CHUQ-CHUL) Research Centre, Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[{"name":"Paris Descartes University, Cochin Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove","family":"T\u00f6rring","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, S\u00f6dersjukhuset, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ran","family":"Ho","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Erik","family":"Beck Jensen","sequence":"additional","affiliation":[{"name":"Hvidovre University Hospital, Hvidovre, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Canterbury Geriatric Medical Research Trust, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Recknor","sequence":"additional","affiliation":[{"name":"United Osteoporosis Centers, Gainesville, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Austin","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Grauer","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Wagman","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"2024020318405393100_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archinte.162.6.665","article-title":"Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Safety Follow-up Study","volume":"162","author":"Greendale","year":"2002","journal-title":"Arch Intern Med."},{"key":"2024020318405393100_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone."},{"key":"2024020318405393100_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s001980170107","article-title":"Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women","volume":"12","author":"Tremollieres","year":"2001","journal-title":"Osteoporos Int."},{"key":"2024020318405393100_bib4","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJM199310143291610","article-title":"The waning effect of postmenopausal estrogen therapy on osteoporosis","volume":"329","author":"Ettinger","year":"1993","journal-title":"N Engl J Med."},{"key":"2024020318405393100_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM199310143291601","article-title":"The effect of postmenopausal estrogen therapy on bone density in elderly women","volume":"329","author":"Felson","year":"1993","journal-title":"N Engl J Med."},{"key":"2024020318405393100_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09513598709030680","article-title":"Bone turnover in postmenopausal women after withdrawal of estrogen\/gestagen replacement therapy","volume":"1","author":"Thomsen","year":"1987","journal-title":"Gynecol Endocrinol."},{"key":"2024020318405393100_bib7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","article-title":"Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial","volume":"163","author":"Ascott-Evans","year":"2003","journal-title":"Arch Intern Med."},{"key":"2024020318405393100_bib8","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318405393100_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med."},{"key":"2024020318405393100_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S8756-3282(03)00171-6","article-title":"Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study","volume":"33","author":"Sornay-Rendu","year":"2003","journal-title":"Bone."},{"key":"2024020318405393100_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Santora AC 2nd. Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause."},{"key":"2024020318405393100_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.1997.03540310041032","article-title":"Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study","volume":"277","author":"Schneider","year":"1997","journal-title":"JAMA."},{"key":"2024020318405393100_bib13","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA."},{"key":"2024020318405393100_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","article-title":"Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study","volume":"10","author":"Barrett-Connor","year":"2003","journal-title":"Menopause."},{"key":"2024020318405393100_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.AOG.0000114986.14806.37","article-title":"Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment","volume":"103","author":"Yates","year":"2004","journal-title":"Obstet Gynecol."},{"key":"2024020318405393100_bib16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA."},{"key":"2024020318405393100_bib17","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med."},{"key":"2024020318405393100_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020318405393100_bib19","first-page":"1725","volume-title":"Bisphosphonates: pharmacology and use in the treatment of osteoporosis","author":"Miller","year":"2008","edition":"3rd edition"},{"key":"2024020318405393100_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone."},{"key":"2024020318405393100_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int."},{"key":"2024020318405393100_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int."},{"key":"2024020318405393100_bib23","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA."},{"key":"2024020318405393100_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020318405393100_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020318405393100_bib26","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318405393100_bib27","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318405393100_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"key":"2024020318405393100_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat."},{"key":"2024020318405393100_bib30","year":"2012"},{"key":"2024020318405393100_bib31","year":"2010"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1808","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.1808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.1808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/746\/56562996\/1808_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/4\/746\/56562996\/1808_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:48:09Z","timestamp":1710326889000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/4\/746-752\/7598611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,10,1]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1808","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2013,4,1]]}}}